SCHEMBL16340735

SCHEMBL16340735

NCCCOCCOCCOCCOCCOCCCNc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)C(O)[C@@H]1O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 5/20 0.78
P2RX2 Q9UBL9 5/20 0.78
GPR17 Q13304 1/20 0.66
NT5E P21589 1/20 0.65
P2RX4 Q99571 2/20 0.65
P2RY1 P47900 5/20 0.61
P2RY2 P41231 3/20 0.61
P2RX1 P51575 2/20 0.61
SRC P12931 1/20 0.61
ALDH1A1 P00352 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
P2RY6 Q15077 1/20 0.60
P2RY12 Q9H244 1/20 0.60
RNASEL Q05823 1/20 0.59
MACROD2 A1Z1Q3 1/20 0.58
SIRT6 Q8N6T7 1/20 0.58
MACROD1 Q9BQ69 1/20 0.58
TRPM2 O94759 1/20 0.58
DNPH1 O43598 1/20 0.57
TAS1R3 Q7RTX0 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14948867 1.00 P2RX3 (0.78) P2RX3P2RX2GPR17NT5EP2RX4
SCHEMBL18574267 1.00 P2RX3 (0.78) P2RX3P2RX2GPR17NT5EP2RX4
SCHEMBL14946381 1.00 P2RX3 (0.78) P2RX3P2RX2GPR17NT5EP2RX4
SCHEMBL14946188 0.98 P2RX3 (0.76) P2RX3P2RX2GPR17NT5EP2RX4
SCHEMBL14948866 0.93 P2RX3 (0.66) P2RX3P2RX2GPR17NT5EP2RX4
SCHEMBL4208216 0.93 P2RX3 (0.84) P2RX3P2RX2GPR17NT5EP2RX4
SCHEMBL15038135 0.93 P2RX3 (0.70) P2RX3P2RX2GPR17NT5EP2RX4
SCHEMBL8738522 0.92 P2RX3 (0.82) P2RX3P2RX2GPR17NT5EP2RX4
SCHEMBL4217929 0.92 P2RX3 (0.82) P2RX3P2RX2GPR17NT5EP2RX4
SCHEMBL30853828 0.92 P2RX3 (0.82) P2RX3P2RX2GPR17NT5EP2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF MODERNATX, INC. 2017-03-02 US disclosed
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF MODERNATX, INC. 2017-03-02 US disclosed
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF modeRNA Therapeutics (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123481-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 P2RX3 736/4885P2RX2 904/4885GPR17 1159/4885
US-20170056528-A1 MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF ADAR, NT5C3B, NSUN2 P2RX3 736/4885P2RX2 904/4885GPR17 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.